Renowned Proteomic Researchers to Present Quantum-Si Data at World HUPO 2024
10 10월 2024 - 7:00PM
Business Wire
Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or
the “Company”), The Protein Sequencing Company™, today announced
its participation at the Human Proteome Organization (HUPO) World
Congress 2024 in Dresden, Germany. As a leader in Next-Generation
Protein Sequencing™ (NGPS), Quantum-Si will be joined by prominent
researchers to present data showcasing advancements in proteomic
analysis.
Quantum-Si’s latest developments, featuring data from Platinum®,
the world’s first and only NGPS instrument on the market, will be
highlighted in two key poster sessions:
Poster Presentations:
- Quantum-Si’s Next-Generation Protein Sequencer™ Enables Protein
Detection and Peptide Characterization from Biological Samples
- Presented by John Kudolo, PhD, Quantum-Si
- Poster ID: P-III-0753 | Date: Wednesday, October 23
- Integrated Sequencing of Single Transcript and Protein
Molecules Discerns Alternatively Spliced Tropomyosin Proteoforms
- Presented by Gloria Sheynkman, PhD, University of Virginia
- Poster ID: P-III-0758 | Date: Wednesday, October 23
In addition to the poster presentations, Quantum-Si will host a
breakfast talk on Tuesday, October 22, titled “Joining Forces:
Next-Generation Protein Sequencing™ and Top-Down Mass Spectrometry
Combine to Enhance Proteoform Analysis.” The session will be led by
Dr. Meredith Carpenter, Quantum-Si’s Head of Scientific Affairs,
and Dr. Neil Kelleher from Northwestern University.
These presentations will showcase new data demonstrating how
Platinum addresses applications including detection of protein
variants and post-translational modifications, protein barcoding,
and characterization of proteoforms in tandem with top-down mass
spectrometry.
"We are honored to have such accomplished researchers presenting
data from Platinum at HUPO 2024,” said Jeff Hawkins, Chief
Executive Officer of Quantum-Si. “The ability to detect and
characterize proteins and peptides with such depth and precision is
a significant step forward for proteomic research. We continue to
believe our technology has the potential to transform how
scientists approach biological discovery."
For more information about Quantum-Si’s innovative solutions and
to meet the team at World HUPO 2024, attendees can visit booth
#24.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on
revolutionizing the growing field of proteomics. The Company’s
Platinum® instrument enables Next-Generation Protein Sequencing™
that advances proteomic research, drug discovery, and diagnostics
beyond what has been possible with existing proteomic tools. Learn
more at quantum-si.com or follow us on LinkedIn or X.
Forward Looking Statements
This press release includes "forward-looking statements" within
the meaning of the "safe harbor" provisions of the United States
Private Securities Litigation Reform Act of 1995. The actual
results of the Company may differ from its expectations, estimates,
and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as "expect," "estimate," "project," "budget," "forecast,"
"anticipate," "intend," "plan," "may," "will," "could," "should,"
"believes," "predicts," "potential," "continue," and similar
expressions (or the negative versions of such words or expressions)
are intended to identify such forward-looking statements. These
forward-looking statements include, without limitation, the
Company's expectations with respect to future performance and
development and commercialization of products and services. These
forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from those discussed in the forward-looking statements.
Most of these factors are outside the Company's control and are
difficult to predict. Factors that may cause such differences
include, but are not limited to: the inability to maintain the
listing of the Company's Class A common stock on The Nasdaq Stock
Market; the ability of the Company to grow and manage growth
profitably and retain its key employees; the Company’s ongoing
leadership transitions; changes in applicable laws or regulations;
the ability of the Company to raise financing in the future; the
success, cost and timing of the Company's product development and
commercialization activities; the commercialization and adoption of
the Company’s existing products and the success of any product the
Company may offer in the future; the potential attributes and
benefits of the Company’s commercialized Platinum™ protein
sequencing instrument and kits and the Company’s other products
once commercialized; the Company's ability to obtain and maintain
regulatory approval for its products, and any related restrictions
and limitations of any approved product; the Company's ability to
identify, in-license or acquire additional technology; the
Company's ability to maintain its existing lease, license,
manufacture and supply agreements; the Company's ability to compete
with other companies currently marketing or engaged in the
development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have
greater financial and marketing resources than the Company; the
size and growth potential of the markets for the Company's products
and services, and its ability to serve those markets once
commercialized, either alone or in partnership with others; the
Company's estimates regarding future expenses, future revenue,
capital requirements and needs for additional financing; the
Company's financial performance; and other risks and uncertainties
described under "Risk Factors" in the Company’s most recent Annual
Report on Form 10-K, and in the Company's other filings with the
SEC. The Company cautions that the foregoing list of factors is not
exclusive. The Company cautions readers not to place undue reliance
upon any forward-looking statements, which speak only as of the
date made. The Company does not undertake or accept any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241010243916/en/
Investor Contact Doug Farrell, VP, Investor Relations
ir@quantum-si.com Media Contact Katherine Atkinson, SVP,
Commercial Marketing media@quantum-si.com
Quantum Si (NASDAQ:QSI)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Quantum Si (NASDAQ:QSI)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025